Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
HYPERION THERAPEUTICS INC (HPTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/07/2015 8-K Form 8-K - Current report
04/09/2015 8-K Results of Operations and Financial Condition
03/30/2015 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Horizon Pharma Inc., Ghrian Acquisition Inc. and Hyperion Therapeutics, Inc",
"Form of Tender and Support Agreement, by and among Horizon Pharma, Inc., Ghrian Aquistion Inc. and each of the Principal Stockholders",
"Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per share or $1.1 Billion in Cash"
02/26/2015 8-K Quarterly results
02/17/2015 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Hyperion Therapeutics Enters Into Completion of Phase III Clinical Trial, Option and Mutual Release Agreement with Clal Biotechnology Industries and Yeda Research and Development Company"
02/10/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/06/2014 8-K Quarterly results
09/08/2014 8-K Material Impairments, Other Events, Financial Statements and Exhibits
Docs: "Hyperion Therapeutics Terminates DiaPep277 ® Program"
08/12/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Hyperion Therapeutics Appoints Theodore Schroeder to Board of Directors"
08/07/2014 8-K Quarterly results
07/21/2014 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Loan and Security Agreement, by and between Silicon Valley Bank and Hyperion Therapeutics, Inc"
07/08/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/13/2014 8-K Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Other Events, Financial Statemen...
Docs: "Hyperion Therapeutics Completes Acquisition of Andromeda Biotech, Ltd."
06/06/2014 8-K Regulation FD Disclosure
05/28/2014 8-K Submission of Matters to a Vote of Security Holders
05/06/2014 8-K Quarterly results
04/24/2014 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Hyperion Therapeutics to Broaden Orphan Disease Pipeline With Acquisition of Andromeda Biotech Ltd."
03/18/2014 8-K Other Events
03/11/2014 8-K Other Events
03/07/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/27/2014 8-K Quarterly results
02/25/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/12/2013 8-K Form 8-K - Current report
04/11/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/25/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/25/2013 8-K Quarterly results
Docs: "Hyperion Therapeutics Announces Fourth Quarter and Full Year 2012 Operating Results South San Francisco, CA - February 25, 2013 - Hyperion Therapeutics, Inc. today reported financial operating results for the fourth quarter and the year ended December 31, 2012. According to Chief Executive Officer, Donald J. Santel, “Since the FDA's approval of RAVICTI™ on February 1st, we have been singularly focused on our commercial roll-out and expect to have product available for launch by the end of April. Specifically, we have begun the training of our sales and market access field teams and have initiated reimbursement dialogues with key private and public payers. We also expect to begin the final due diligence review related to our option to purchase BUPHENYL ® Tablets and Powder and AMMONUL ® inj..."
02/20/2013 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "1†"
01/16/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Hyperion Notified that FDA Will Not Meet the PDUFA Action Date for Ravicti™ South San Francisco, CA - January 16, 2013 - Hyperion Therapeutics, Inc. said that the U.S. Food and Drug Administration has advised the Company not to expect a final action by the Prescription Drug User Fee Act action date of January 23, 2013. The agency explained it is continuing to work on label and post-marketing requirements in connection with Hyperion's New Drug Application for Ravicti™ for the treatment of Urea Cycle Disorders . About Ravicti™ Ravicti, an investigational drug, is a pre-pro-drug of phenylacetic acid, the active moiety of BUPHENYL ® , the only branded therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with the most prevalent urea cycle disorders. Ravict..."
12/04/2012 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Second Amendment to Office Lease by and between the Company and Gateway Center, LLC"
09/06/2012 8-K Quarterly results
Docs: "Hyperion Therapeutics Announces Second Quarter 2012 Operating Results South San Francisco, CA - September 6, 2012 - Hyperion Therapeutics, Inc. today reported consolidated financial results for the second quarter of 2012. The company reported cash and cash equivalents of $7.3 million as of June 30, 2012. Subsequent to the end of the quarter, on July 31, 2012, the company successfully closed its initial public offering and the underwriters exercised their over-allotment option in full raising proceeds, net of underwriter discounts, of $53.5 million. The company intends to use the proceeds primarily for the potential launch of its first drug, Ravicti ™ . According to Chief Executive Officer, Donald J. Santel, “Having a completed IPO makes us well positioned for the potential approval and lau..."
08/28/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/31/2012 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Amended and Restated Certificate of Incorporation of the Company"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy